Ketamine Infusion Denied by Insurance? Appeals Guide for Treatment-Resistant Depression

IV ketamine infusion is a rapidly growing treatment for severe, treatment-resistant depression (TRD), and in many cases it produces dramatic improvement in patients who have failed multiple other treatments — including relief of acute suicidal ideation within hours. Despite this, insurance companies almost universally deny IV ketamine infusion for one primary reason: it is administered off-label. Understanding why this denial happens and how to challenge it is essential if you or a loved one needs this treatment.

Why IV Ketamine Is Almost Always Denied — And Why That May Be Unlawful

Ketamine (as an anesthetic agent) is FDA-approved, but its use for depression is considered off-label because the FDA has not specifically cleared it for that indication. Most insurance plans exclude off-label treatments — but that exclusion is not always legally enforceable.

The off-label exclusion and Mental Health Parity Act (MHPAEA) Explained" class="auto-link">MHPAEA. If your plan covers off-label use of medications or procedures for medical or surgical conditions, it cannot categorically deny off-label treatments for mental health conditions without violating MHPAEA. For example, many oncology regimens involve off-label use of chemotherapy agents — and most plans cover these. If your plan covers off-label cancer treatments while categorically excluding off-label mental health treatments, that disparity is a parity violation.

The "experimental" argument. Some insurers deny IV ketamine as experimental or investigational. This argument is increasingly difficult to sustain given the volume of published clinical evidence, the existence of major academic medical centers offering IV ketamine infusion programs, and the FDA's own approval of esketamine (Spravato) — a closely related compound — specifically for TRD. If the FDA has approved a related molecule for the same indication, the "experimental" argument for IV ketamine is substantially weakened.

Systematic exclusion of mental health treatments. A blanket plan exclusion of all off-label mental health treatments — while covering off-label treatments for medical conditions — is itself a MHPAEA violation regardless of the specific drug at issue.

IV Ketamine vs. Spravato (Esketamine): Understanding the Distinction

Spravato (esketamine) is FDA-approved for treatment-resistant depression and for major depressive disorder with acute suicidal ideation or behavior. It is administered as a nasal spray in a certified healthcare facility under REMS supervision.

IV ketamine infusion uses racemic ketamine (a combination of R and S enantiomers) delivered intravenously. It is faster-acting, more customizable in dosing, and many psychiatrists consider it more effective for acute suicidal ideation. However, because it is off-label, it is much harder to get covered.

If IV ketamine is denied, one appeal strategy is to document why Spravato is not an adequate alternative — for example, if the patient has tried Spravato without adequate response, or if IV administration is clinically necessary due to absorption or tolerability issues.

Building Your IV Ketamine Appeal

Your appeal should include:

• Documentation of treatment-resistant depression: At least two adequate, failed antidepressant trials (specific drugs, doses, duration, outcome).
• Treating psychiatrist's letter documenting TRD, clinical rationale for IV ketamine, and why FDA-approved alternatives have been tried and failed or are not appropriate.
• Published clinical evidence supporting IV ketamine for TRD — there are multiple peer-reviewed meta-analyses and randomized controlled trials.
• A MHPAEA parity argument comparing the plan's off-label coverage policy for medical vs. mental health treatments.
• Plan document review: Extract the exact language of any off-label exclusion and identify comparable off-label medical treatments the plan covers.

State Laws on Off-Label Coverage

Several states require insurers to cover off-label use of FDA-approved drugs when supported by peer-reviewed clinical evidence. These states include California, Illinois, and others with "any willing provider" or off-label drug coverage mandates. If your state has such a law, cite it explicitly in your appeal.

The External Independent Review: Complete Guide" class="auto-link">External Review Option

IV ketamine denials have a realistic chance of reversal in external independent review when the appeal is well-documented. External reviewers apply generally accepted clinical standards and cannot simply defer to the insurer's "off-label" exclusion if that exclusion violates parity or state law.

Fight Back With ClaimBack

IV ketamine denials are complex — they involve parity law, off-label coverage policy, and the intersection of federal and state regulation. ClaimBack helps you navigate these layers and build an appeal that addresses every angle.

Start your ketamine infusion appeal at ClaimBack and fight for the treatment that could save your life.

Related Reading

• How to Write an Insurance Appeal Letter
• What Is Medical Necessity?
• Common Reasons Insurance Claims Are Denied